Monitor draw down activity under the GEM facility; each draw down at a 10% discount to market will pressure the stock. Watch for Phase 2b topline results for GX-03 in AD expected Q1 2027, which could alter the capital narrative.
Drug in focus
TTRX drug pipeline →GX-03
▲ Bullish Named in this S-3- Impact
- Phase
- Phase 2
- Time to market
- ~3-4 years if Phase 2 succeeds; GX-03 needs Phase 3 trials (estimated $55-60M R&D spend per company guidance) and FDA approval. Cash runway only through Q1-Q3 2027, so additional financing likely needed.
- Next catalyst
- None dated
What to watchGX-03 Phase 2 topline data in Q4 2026 is the next binary inflection point. Interim data (June 2026) showed strong efficacy signals (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with zero serious adverse events. The expanded Stage 2 (~120-135 patients) and planned FDA Type-B meeting make Q4 the key catalyst window. Monitor enrollment updates and any competitive landscape shifts from approved topicals (ruxolitinib, roflumilast).
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $9.79entry
- T+1 · 7d ago +1.33%α +1.70% · $9.92
- T+5 · 17h ago −12.67%α −10.97% · $8.55
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Turn Therapeutics filed an S-3 shelf registration to register the resale of 25,362,950 shares by selling stockholders, including up to 6,621,190 shares from GEM under an existing $85M committed equity facility. The company will not receive proceeds from the resale but may draw up to $85M from GEM for working capital. The registered shares represent 82.96% of outstanding shares, creating significant potential overhang. The filing coincides with a Q3 2026 net loss of $6.2M and $10.4M cash on hand, indicating a capital need.
Key Financial Metrics
Key Facts
- S-3 registers resale of 25,362,950 shares, representing 82.96% of 30,572,704 shares outstanding as of Nov 6, 2026
- Includes up to 6,621,190 shares from GEM under an $85M committed equity facility (GEM Purchase Agreement)
- Company may receive up to $85M from future draw downs to GEM; $75M remains available after $4.07M initial draw and $2.72M second draw
- GEM purchases shares at 90% of average daily closing price over 15-day pricing period, floor of $1.00 per share
- Q3 2026 net loss of $6.2M vs $1.9M in Q3 2025; cash of $10.4M funds operations into Q3 2027 per prior 8-K
- 9 offering/registration filings in last 24 months; pre-revenue clinical-stage biotech with no approved products
Financial Impact
Potential dilution of up to 82.96% of current shares outstanding; $85M equity facility available at 90% of market price
Risk Factors
- Massive potential dilution: 25.36M registered shares vs 30.57M outstanding creates severe overhang
- GEM facility pricing at 90% of market with $1.00 floor encourages repeated dilutive draws
- Pre-revenue with widening losses ($6.2M in Q3 2026) and limited cash runway ($10.4M)
- No approved products; clinical-stage risk with GX-03 Phase 2b data not expected until Q1 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001213900-26-117224 |
| Document: ea031087401ex-fee.htm | 0001213900-26-117224 |
| Document: ea031087401ex5-1.htm | 0001213900-26-117224 |
| Document: ea031087401ex23-1.htm | 0001213900-26-117224 |
| Document: 0001213900-26-117224-index-headers.html | 0001213900-26-117224 |
| Document: 0001213900-26-117224-index.html | 0001213900-26-117224 |
| Document: 0001213900-26-117224.txt | 0001213900-26-117224 |
Track record
19 reports on TTRX
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +115.10% at T+60 after the May 18, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry $8.55 Now $8.55 −0.00% settles Feb 16
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $9.92 Now $8.55 −13.81% settles Feb 8
- Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
- Nov 9, 20267d ago S-3 Bearish 6/10 Viewing Entry $9.79 Now $8.55 +12.67% settles Feb 5
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $9.79 Now $8.55 −12.67% settles Feb 5
- Oct 19, 202628d ago DEF 14A Neutral 3/10 Entry $10.47 Now $8.55 −18.34% settles Jan 15
- Oct 6, 20265w ago 8-K Neutral 5/10 Entry $12.10 Now $8.55 −29.34% settles Jan 4
- Sep 10, 20269w ago 8-K Neutral 3/10 Entry $13.38 Now $8.55 −36.10% settles Dec 4
- Sep 9, 20269w ago 8-K Bullish 5/10 Entry $13.75 Now $8.55 −37.82% settles Dec 3
- Aug 18, 202612w ago 8-K Neutral 4/10 Entry $9.99 to $9.92 Now $8.55 −14.41% ▼ −0.70% +1.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers